Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Jul 10, 2019 11:42am
101 Views
Post# 29904153

RE:RE:RE:Stage is set for tomorrows call... down -4.5%

RE:RE:RE:Stage is set for tomorrows call... down -4.5%I’d have to agree with your concerns and frustrations. The silver lining for me on this most recent drift lower is the anemic volumes. The summer holiday season hits hard as Canada day and July 4th celebrations mean many could be away from the office. I can only hope that volumes and buying pick up after next week once the analyst reports are out and people are back at their desks.

It will be up to management to set the tone for the summer. European approval and a NASH journal publication are out of managements hands, so they better not be relying on “pending events” to help sell the Q2 story. They need to put a focus on communicating their sales forecasts and expectations to clearly give the market an idea of the future.

I would also expect an update on the Nasdaq listing. After mentioning they were exploring the idea after Q1, I would be extremely frustrated if little progress has been made over the last two months.

Management needs to put a little less focus on the “next billion” and make sure they are executing on the things that should be getting us back to the first billion.  

Bullboard Posts